Table 2:
Lipidomic studies reporting prognostic lipid signatures in biofluids
| Cancer type | Samples | Outcome | MS | biofluid | Lipids altered | Reference |
|---|---|---|---|---|---|---|
| Measure | Platform | |||||
| Lung | 300 Pre-treatment | Risk of cancer development | LC//MS | Plasma | Shingosine 1-phosphate | Alberg et al, 2013 [9] |
| Prostate | 3,057 Matched case-controls (EPIC study) | Development of advanced or aggressive prostate cancer | MS) | Plasma | PCs, lysoPCs | Schmidt et al, 2020 [10] |
| Hepatocellular carcinoma | 43 | Responders vs non-responders to sorafenib | RPLC-MS | Plasma | PC34:2; PC34:3; PC35:2; PC36:4a; PC34:3e; acylcarnitine (18:0); cholesterol ester (20:2); DG34:2 | Saito et al, 2018 [11] |
| Ovarian | 101 | Recurrence vs non-recurrence following standard of care therapy | UPLC-MS | plasma | 31 lipids predicted recurrence; LPG20:5 increased predictive power of current clinical predictors; reduced triacylglycerides predicted early relapse | Li et al, 2017 [12] |
| Prostate | 159 | Overall survival | LC-MS/MS | plasma | Cer (d18:1/24:1); SM(d18:2/16:0); PC(16:0/16:0) | Lin et al, 2017 [13] |